AI Computing Power Empowers Pharmaceutical Dividend Stocks: Technological Transformation and Valuation Reshaping in US High-Dividend Pharmaceutical Companies

In the context of the new drug discovery efficiency bottleneck in the global pharmaceutical industry in 2026, breakthroughs in AI computing chips bring new growth momentum to high-dividend pharmaceutical companies. Traditional new drug development cycles are long and costly, whereas AI computing chips significantly enhance R&D efficiency by accelerating drug molecule screening and optimizing clinical trial design. This article will deeply analyze how AI computing chips empower US high-dividend pharmaceutical stocks, exploring their technological transformation path and valuation reshaping logic to provide reference for investors. ## I. AI Computing Chips: The "Accelerator" for Pharmaceutical R&D As core hardware for artificial intelligence technology, the performance improvements of AI computing chips are driving a revolution in pharmaceutical R&D efficiency. In recent years, computing chips like NVIDIA's H100 and AMD's MI400X, launched by chip giants, enable complex computational tasks such as drug molecule simulation and protein structure prediction to be completed in a short time through powerful parallel computing capabilities. For example, Pfizer utilized the NVIDIA H100 chip to reduce drug molecule screening time from several weeks to a few days, significantly lowering R&D costs. In the drug discovery stage, AI computing chips can simulate the interaction between drugs and targets, rapidly screening out potential active molecules. Traditional methods require synthesizing thousands of compounds for testing, while AI computing chips use machine learning models to predict the biological activity of compounds, narrowing the screening scope to dozens, saving significant time and funds. Furthermore, AI computing chips can optimize clinical trial design by analyzing patient data to precisely match suitable trial populations, thereby increasing the trial success rate. ### 1.1 Drug Molecule Screening: From "Fishing in a Sea of Fish" to "Precision Targeting" Drug molecule screening is a critical stage in new drug development, but traditional methods rely on experimental verification, leading to low efficiency. AI computing chips can quickly predict the pharmacological activity of drug molecules through deep learning models. For instance, Janssen utilized the AMD MI400X chip to build a large-scale drug molecule database, predicting the binding ability of molecules to targets with AI models, increasing screening efficiency by over 50%. Additionally, AI computing chips can simulate the metabolic process of drugs in vivo, predicting toxicity and side effects, thereby pre-excluding ineffective molecules. This "virtual screening" method not only saves experimental costs but also reduces R&D risks. ### 1.2 Clinical Trial Optimization: The Key to Improving Success Rates Clinical trials are the most time-consuming and expensive stages in drug development, and traditional designs often rely on experience, leading to high failure rates. AI computing chips can optimize trial design by analyzing historical clinical trial data and precisely matching patient populations. For example, Merck analyzed thousands of clinical trial data points using the NVIDIA Blackwell Ultra chip to build patient stratification models, increasing the trial success rate by over 20%. Furthermore, AI computing chips can monitor trial data in real-time to detect anomalies and adjust trial protocols promptly. This "dynamic optimization" method makes clinical trials more efficient and shortens the R&D cycle. ## II. AI Transformation in High-Dividend Pharmaceutical Stocks: Case Analysis US high-dividend pharmaceutical stocks such as Pfizer, Janssen, and Merck are actively deploying AI computing chip technology to enhance competitiveness through technological transformation. These companies not only enjoy stable dividend income but also achieve a balance between growth and defense by developing new drugs through AI. ### 2.1 Pfizer: Dual Engine Driven by AI and New Drug Discovery PharmaCo has increasingly applied AI in new drug discovery as a leading pharmaceutical enterprise globally. In 2025, PharmaCo partnered with NVIDIA to introduce H100 computing chips and establish an AI drug discovery platform. This platform can rapidly screen drug molecules, accelerating the development process for oncology drugs. In Q2 2026, PharmaCo's AI research project achieved a breakthrough, with a new oncology drug entering clinical trials, expected to launch in 2027. Furthermore, PharmaCo raised its dividend, with the dividend yield reaching 3.5% in 2026, higher than the industry average. Analysts believe that PharmaCo's AI strategy not only enhances R&D efficiency but also strengthens its long-term competitiveness, ensuring stable dividend returns even at the end of a dividend cycle. ### 2.2 Jiangsu: AI Empowering Personalized Medicine Jiangsu Company is promoting the development of personalized medicine through AI computing chips. In 2025, Jiangsu partnered with AMD to build a personalized medicine database using the MI400X chip, analyzing patient gene data and clinical data to provide customized treatment plans for patients. For example, Jiangsu's AI platform can predict the response rate of patients to a certain drug, adjusting dosage regimens to improve treatment efficacy. Jiangsu's dividend has shown continuous growth, reaching a dividend yield of 4.2% in 2026. Analysts point out that Jiangsu's AI strategy not only increases patient satisfaction but also adds value to its products, allowing it to maintain a leading position in the competitive pharmaceutical market. ### 2.3 Merck East: AI Accelerating Vaccine Development Merck East has significantly shortened the R&D cycle in vaccine development by applying AI computing chips. In 2025, Merck East utilized the NVIDIA Blackwell Ultra chip to accelerate the development of COVID-19 vaccines, enabling new vaccines to complete clinical trials within 6 months, shortening the time by one year compared to traditional methods. Merck East's dividend has shown 10 consecutive years of growth, reaching a dividend yield of 3.8% in 2026. Analysts believe that Merck East's AI strategy gives it an advantage in the vaccine market, while stable dividend returns provide investors with defensive stability. III. Investment Logic: Balancing Dividend and Growth For investors, the AI transformation in high-dividend pharmaceutical stocks brings dual returns: stable dividend income and growth potential. At the end of a dividend cycle, market risk appetite decreases, highlighting the defensive nature of high-dividend stocks; meanwhile, the increased R&D efficiency brought by AI creates growth space for these companies. ### 3.1 Dividend Stability: The Core of Defense The dividend stability of high-dividend pharmaceutical stocks is key to attracting investors. Companies like PharmaCo and Jiangsu have stable cash flows and can continue paying dividends. For instance, PharmaCo's dividend has grown for 20 consecutive years, and Jiangsu's dividend has grown for 30 consecutive years. During market fluctuations, the dividends from these companies can provide investors with stable cash flow, reducing investment risk. ### 3.2 Growth Potential from AI: The Key to Valuation Reshaping The application of AI computing chips enhances the R&D efficiency of high-dividend pharmaceutical stocks, speeds up the time to market for new drugs, thereby increasing their revenue and profits. For example, PharmaCo's AI R&D project is expected to generate $1 billion in revenue in 2027, and Jiangsu's personalized medicine platform is expected to generate $1.5 billion in revenue in 2028. These growth factors reshape the valuation of high-dividend pharmaceutical stocks, transforming them from traditional defensive stocks into premium assets of "defense + growth".

3.3 Investment Recommendations: Focus on Companies Leading in AI Layout

Investors should focus on high-dividend pharmaceutical stocks leading in the application of AI computing chips, such as Pfizer, AstraZeneca, and MSD. These companies not only have stable dividend income but also achieve improvements in R&D efficiency through AI, possessing long-term investment value. Furthermore, investors can look at AI pharmaceutical ETFs, such as iShares U.S. Pharmaceutical ETF (PJP), which holds companies like Pfizer and AstraZeneca, to diversify risk.

Four, Conclusion

Breakthroughs in AI computing chip technology bring new growth momentum to US high-dividend pharmaceutical stocks. By empowering new drug R&D with AI, these companies not only improve R&D efficiency but also achieve a balance between growth and defense. At the tail end of the interest rate cycle, the AI transformation of high-dividend pharmaceutical stocks makes them an important choice for investors. In the future, with further development in AI computing chip technology, the valuation of high-dividend pharmaceutical stocks is expected to continue to rise, bringing double returns to investors.